Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: A network meta-analysis

Thorax

Volumn 71, Issue 1, 2016, Pages 15-25

  Oba, Yuji ^a   Sarva, Siva T ^a   Dias, Sofia ^b  

^a University of Missouri   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG COMBINATION;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEART DISEASE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE ASSESSMENT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TRANSITIONAL DYSPNOEA INDEX; DRUG COMBINATION; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; DRUG COMBINATIONS; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 84958166671     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206732     Document Type: Article

References (43)

1. World Health Organization Chronic respiratory diseases. Global surveillance, prevention and control of chronic respiratory diseases. Chronic obstructive pulmonary disease. http://www.who.int/respiratory/copd/en (accessed 12 Dec 2014).
2. Dalal AA, Christensen L, Liu F, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 2010;5:341-9.
3. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
4. Cazzola M, Lopez-Campos JL, Puente-Maestu L. The MABA approach: a new option to improve bronchodilator therapy. Eur Respir J 2013;42:885-7.
5. Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD-role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis 2014;9:687-95.
6. Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis 2013;7:311-19.
7. Beeh KM. "All I want for christmas is two": the advent of novel fixed-combination inhalers for COPD and outlook for 2014. Adv Ther 2013;30:1033-7.
8. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
9. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21:267-72.
10. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
11. Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17.
12. Toft N, Innocent GT, Gettinby G, et al. Assessing the convergence of Markov Chain Monte Carlo methods: an example from evaluation of diagnostic tests in absence of a gold standard. Prev Vet Med 2007;79:244-56.
13. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
14. Spiegelhalter DJ, Best NG, Carlin BP, et al. Bayesian Measures of Model Complexity and Fit. J R Stat Soc Series B Stat Methodol 2002;64:583-639.
15. Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 2013;33:641-56.
16. Dias S, Sutton AJ, Welton NJ, et al. Evidence synthesis for decision making 3: heterogeneity - subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making 2013;33:618-40.
17. Bhaumik DK, Amatya A, Normand SL, et al. Meta-Analysis of Rare Binary Adverse Event Data. J Am Stat Assoc 2012;107:555-67.
18. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Syst Rev 2012;1:41.
19. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015;45:969-79.
20. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014;145:981-91.
21. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014;2:472-86.
22. D'Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014;15:123.
23. Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 2014;108:1752-60.
24. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014;14:178.
25. Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014;9:215-28.
26. ZuWallack R, Allen L, Hernandez G, et al. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis 2014;9:1133-44.
27. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-94.
28. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013;107:1558-67.
29. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107:1538-46.
30. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209.
31. Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014;15:78.
32. GlaxoSmithKline. An exercise endurance study to evaluate the effects of treatment of Chronic Obstructive Pulmonary Disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study A. 2012. http://www.gsk-clinicalstudyregister.com/search?study-ids=DB2114417#ps (accessed 11 Dec 2014).
33. GlaxoSmithKline. An exercise endurance study to evaluate the effects of treatment of Chronic Obstructive Pulmonary Disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study B. 2012. http://www.gsk-clinicalstudyregister.com/search?study-ids=2114418#ps (accessed 12 Dec 2014).
34. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67:781-8.
35. Novartis A 52-week treatment, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of QVA149 (110 mcg indacaterol/50 mcg glycopyrrolate o.d.) using tiotropium (18 mcg o.d.) as an active control in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD). 2012. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?divisionId=2&productID=650&diseaseAreaID=9 (accessed 12 Dec 2014).
36. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009;6:17-25.
37. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102:1511-20.
38. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55.
39. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Statist 1998;7:434-55.
40. Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;4:CD008989.
41. Oba Y, Lone N. Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression. Ther Adv Respir Dis 2015;9:3-15.
42. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115:635-41.
43. Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014;17:157-73.